Cheng Sohanya Roshan 4
4 · Karyopharm Therapeutics Inc. · Filed May 15, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) EVP Cheng Sohanya Roshan Receives Award, Sells Shares
What Happened
Cheng Sohanya Roshan, EVP & Chief Commercial Officer of Karyopharm Therapeutics (KPTI), had 947 performance-based restricted stock units (PSUs) vest on May 13, 2026 (awarded at $0.00). The next day, 324 of those shares were sold in an open-market broker-assisted sale at $9.50 per share for proceeds of $3,078 to satisfy tax withholding. Net from the vesting event, Roshan retained 623 shares (947 vested − 324 sold).
Key Details
- Transaction dates and prices:
- 2026-05-13: Award/acquisition of 947 shares @ $0.00 (PSUs vested)
- 2026-05-14: Sale of 324 shares @ $9.50 = $3,078 (broker-assisted)
- Shares owned after transaction: Net increase of 623 shares from this vesting event (total holdings after the transaction not specified in the filing excerpt).
- Footnotes:
- F1: The 947 shares are PSUs granted in Feb 2024, earned after achieving a clinical milestone (complete enrollment in the Phase 3 XPORT-EC-042 trial) and certified by the Compensation Committee on May 13, 2026.
- F2: The 324-share sale was executed under a durable automatic sale instruction plan (adopted June 7, 2022) to cover withholding tax and was broker-assisted — not a discretionary trade.
- Filing: Report filed May 15, 2026 covering transactions on May 13–14; filing not indicated as late.
Context
This is primarily a compensation vesting event (PSUs earned) with a routine sale to cover taxes. Such tax-withholding sales under an automatic instruction plan are common and do not necessarily signal the insider’s view of the company’s prospects. Purchases or voluntary sales are generally more informative about sentiment than mandatory tax-withholding sales.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-13+947→ 108,264 total - Sale
Common Stock
[F2]2026-05-14$9.50/sh−324$3,078→ 107,940 total
Footnotes (2)
- [F1]Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.